Systemic Sclerosis with Interstitial Lung Disease

Status

Open

Fund Type

Copay
Premium (Medicare Part B only)

Maximum Award Level

$9,000

Pharmacy Card Fund

Yes

Minimum Copay
Reimbursement Amount

Minimum Copay Reimbursement Amount

We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.

None

Minimum Premium
Reimbursement Amount

Minimum Premium Reimbursement Amount

We encourage you to please submit monthly reimbursement claims (even if your premium is paid on a bi-weekly basis).

None

Household Income Limit

500% of the Federal Poverty Level
(adjusted for household size and high
cost of living areas)

Fund Alerts

Sign up for email or text/call alerts to receive instant notifications.

Treatments Covered

  • Actemra
  • Actemra Actpen
  • Cellcept
  • Cyclophosphamide-monohydrate
  • Cyclophosphamide-novaplus
  • Ofev
  • Premierprorx-cyclophosphamide
  • Rituxan
  • Tofidence

Fund Definition

Assistance with the prescription drugs and biologics used in the treatment of systemic sclerosis with interstitial lung disease..

Grant Utilization

HealthWell estimates that patients use an average of $6,060 during their 12-month grant period for this disease area.

Do I Qualify?

HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:

  • Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Diseases and Medications listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.

  • To qualify for copayment assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. Please note that in order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.

  • HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.

  • If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.

About Systemic Sclerosis with Interstitial Lung Disease 

Scleroderma is a rare disease that affects connective tissue and the vascular system by producing excessive collagen. This causes fibrosis in the skin (localized) or internal organs (systemic sclerosis). The result can be disfigurement or disability, and it can be life-threatening. No one knows what causes scleroderma and there is no cure. Systemic sclerosis is one of the most difficult autoimmune diseases to manage. The disease primarily affects females from 20 to 50 years of age but can also occur in children, men and older adults. More severe and earlier onset has been observed in African Americans and Native Americans. Diffuse scleroderma is the most severe form of systemic sclerosis and involves fibrosis of major organs, especially the lungs. Interstitial lung disease (ILD) is the development of inflammation and/or scarring around the air sacs of the lungs. Worsening or progressive scarring can make it difficult for the lungs to work properly, resulting in declined lung function. Source: National Scleroderma Foundation

 

Additional Educational Resources

You may also visit our Resource List to view other copayment organizations that may provide assistance.